Drug Shortage Report for DOXORUBICIN HYDROCHLORIDE INJECTION

Last updated on 2025-04-24 History
Report ID 249210
Drug Identification Number 02409275
Brand name DOXORUBICIN HYDROCHLORIDE INJECTION
Common or Proper name DOXORUBICIN INJ 50MG/25ML
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) DOXORUBICIN HYDROCHLORIDE
Strength(s) 2MG
Dosage form(s) SOLUTION
Route of administration INTRAVESICAL INTRAVENOUS INTRAVESICAL INTRAVENOUS
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes 25ml
ATC code L01DB
ATC description CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2025-01-30
Estimated end date 2025-05-10
Actual end date 2025-04-16
Shortage status Resolved
Updated date 2025-04-24
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v15 2025-04-24 French Compare
v14 2025-04-24 English Compare
v13 2025-04-10 French Compare
v12 2025-04-10 English Compare
v11 2025-03-27 French Compare
v10 2025-03-27 English Compare
v9 2025-02-28 French Compare
v8 2025-02-28 English Compare
v7 2025-02-20 French Compare
v6 2025-02-20 English Compare
v5 2025-02-13 French Compare
v4 2025-02-13 English Compare
v3 2025-01-31 English Compare
v2 2025-01-30 French Compare
v1 2025-01-30 English Compare

Showing 1 to 15 of 15